WHO Sounds Alert Over Critical Scarcity of Weight-Loss Jabs
Under 10% of individuals that would benefit from GLP-1 drugs including Wegovy are able to get them, caution the WHO as it releases its inaugural guidance on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidelines recognises that excess weight is a lifelong illness that can be addressed with holistic and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major obstacles to universal availability to the injections that can assist patients in reducing substantial weight, explains the agency.
Weight-Loss Drug Shortage
Despite the present most favorable case, the production of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, per the health organization.
The recommendation urges countries and companies to expand access, by measures including licensing agreements.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is due to expire in several countries in 2026.
The Way Weight-Loss Drugs Operate
The injections imitate a natural hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so individuals consume fewer calories.
Patients usually start to lose weight in the initial weeks of beginning the regular doses.
Evidence indicates users may regain a significant portion within a year of discontinuing the medication, because their normal food cravings return.
Being carrying excess weight raises your risk for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight impacts individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
